Encinas-Basurto, D.; Konhilas, J.P.; Polt, R.; Hay, M.; Mansour, H.M.
Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release. Pharmaceutics 2022, 14, 587.
https://doi.org/10.3390/pharmaceutics14030587
AMA Style
Encinas-Basurto D, Konhilas JP, Polt R, Hay M, Mansour HM.
Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release. Pharmaceutics. 2022; 14(3):587.
https://doi.org/10.3390/pharmaceutics14030587
Chicago/Turabian Style
Encinas-Basurto, David, John P. Konhilas, Robin Polt, Meredith Hay, and Heidi M. Mansour.
2022. "Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release" Pharmaceutics 14, no. 3: 587.
https://doi.org/10.3390/pharmaceutics14030587
APA Style
Encinas-Basurto, D., Konhilas, J. P., Polt, R., Hay, M., & Mansour, H. M.
(2022). Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release. Pharmaceutics, 14(3), 587.
https://doi.org/10.3390/pharmaceutics14030587